IMM 201

Drug Profile

IMM 201

Alternative Names: DAR 901; Heat-killed Mycobacterium vaccae strain NCTC 11659; IMM-201; SRL 172

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Silence Therapeutics
  • Developer Aeras; Geisel School of Medicine; Immodulon Therapeutics; Tokyo Medical and Dental University; University of Colorado at Boulder
  • Class Adjuvants; Antineoplastics; Antivirals; Tuberculosis vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis
  • Preclinical Post-traumatic stress disorders
  • Discontinued Asthma; Atopic dermatitis; Hepatitis B; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Prostate cancer; Renal cancer; Seasonal allergic rhinitis; Small cell lung cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Tuberculosis(Prevention) in USA (Intradermal, Injection)
  • 21 Jul 2017 Preclinical trials in Post-traumatic stress disorder in USA (Injection) (Immodulon pipeline, July 2017)
  • 21 Jul 2017 Pharmacodynamics data from a preclinical trial in Post-traumatic stress disorder released by Immodulon Therapeutics (Immodulon pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top